Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Population-Based Analysis Of The Use Of Radium-223 For Bone-Metastatic Castration-Resistant Prostate Cancer In Ontario, And Of Factors Associated With Treatment Completion And Outcome.
Cheng S, Arciero V, Goldberg H, Tajzler C, Manganaro A, Kozlowski N, Rowbottom L, McDonald R, Chow R, Vasisht G, Shaji S, Wong ECL, Petrovic M, Zhang L, Phillips C, Zalewski P, Kapoor A, Fleshner NE, Chow E, Emmenegger U. Cheng S, et al. Among authors: kapoor a. Cancer Manag Res. 2019 Oct 31;11:9307-9319. doi: 10.2147/CMAR.S213051. eCollection 2019. Cancer Manag Res. 2019. PMID: 31802949 Free PMC article.
A Phase II, Randomized, Multicenter Study Comparing 10 Months versus 4 Months of Degarelix Therapy in Prolonging the Off Treatment Interval in Men with Localized Prostate Cancer Receiving Intermittent Androgen Deprivation Therapy for Biochemical Recurrence following Radical Local Therapy.
Klotz L, Loblaw A, Siemens R, Ouellette P, Kapoor A, Kebabdjian M, Zhang L, Saad F; Canadian Urology Research Consortium. Klotz L, et al. Among authors: kapoor a. J Urol. 2018 Aug;200(2):335-343. doi: 10.1016/j.juro.2018.03.010. Epub 2018 Mar 11. J Urol. 2018. PMID: 29534997 Clinical Trial.
The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial.
Bjarnason GA, Knox JJ, Kollmannsberger CK, Soulieres D, Ernst DS, Zalewski P, Canil CM, Winquist E, Hotte SJ, North SA, Heng DYC, Macfarlane RJ, Venner PM, Kapoor A, Hansen AR, Eigl BJ, Czaykowski P, Boyd B, Wang L, Basappa NS. Bjarnason GA, et al. Among authors: kapoor a. Eur J Cancer. 2019 Feb;108:69-77. doi: 10.1016/j.ejca.2018.12.006. Epub 2019 Jan 14. Eur J Cancer. 2019. PMID: 30648632 Free article. Clinical Trial.
2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).
Saad F, Aprikian A, Finelli A, Fleshner NE, Gleave M, Kapoor A, Niazi T, North SA, Pouliot F, Rendon RA, Shayegan B, Sridhar SS, So A, Usmani N, Vigneault E, Chi KN. Saad F, et al. Among authors: kapoor a. Can Urol Assoc J. 2019 Oct;13(10):307-314. doi: 10.5489/cuaj.6136. Can Urol Assoc J. 2019. PMID: 31603409 Free PMC article. No abstract available.
2,221 results